Factors associated with relapse in patients with schizophrenia

International Journal of Psychiatry in Clinical Practice

Volumn 17, Issue 1, 2013, Pages 2-9

  San, Luis ^a   Bernardo, Miquel ^b,c   Gómez, Agustín ^d   Peña, Mario ^e  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^e Medical Affairs   (Spain)

Author keywords

Antipsychotic agents; Patient compliance; Schizophrenia; Treatment outcome

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CANNABIS; COCAINE; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; CANNABIS ADDICTION; CLINICAL PRACTICE; COCAINE DEPENDENCE; DISEASE DURATION; EMERGENCY CARE; FAMILY; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHIATRIC DEPARTMENT; RELAPSE; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; COCAINE-RELATED DISORDERS; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; MALE; MARIJUANA ABUSE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SCHIZOPHRENIA; SOCIAL SUPPORT; SPAIN; TIME FACTORS; YOUNG ADULT;

EID: 84873687513     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.3109/13651501.2012.687452     Document Type: Article

References (41)

1. Breiser M, Iacono WG. An update on the epidemiology of schizophrenia. Can J Psychiatry 1990;35:657-68
2. Bromet EJ, Fenning S. Epidemiology and natural history of schizophrenia. Biol Psychiatry 1999;46:871-81
3. Davies LM, Drummond MF. Economics and schizophrenia: the real cost. Br J Psychiatry 1994;25(Suppl):18-21
4. V áz quez-Polo FJ, Negrí n M, Cabasé s JM, S án chez E, Haro JM, Salvador-Carulla L. An analysis of the costs of treating schizophrenia in Spain: a hierarchical Bayesian approach. Ment Health Policy Econ 2005;8:153-65
5. Heider D, Bernert S, Kö n ig HH, Matschinger H, Hogh T, Brugha TS, et al. Direct medical mental health care costs of schizophrenia in France, Germany and the United Kingdom-fi ndings from the European Schizophrenia Cohort (EuroSC). Eur J Psychiatry 2009;24:216-24
6. Samalin L, Blanc O, Llorca PM. Optimizing treatment of schizophrenia to minimize relapse. Expert Rev Neurother 2010;10:147-50
7. Morken G, Widen JH, Grawe RW. Non-adherence to antipsychotic medication, relapse and rehospitalization in recentonset schizophrenia. BMC Psychiatry 2008;8:32
8. Fitzgerald P, de Castella A, Arya D, Simons WR, Eggleston A, Meere S, et al. The cost of relapse in schizophrenia and schizoaffective disorder. Australas Psychiatry 2009;17:265-72
9. Hong J, Windmeijer F, Novick D, Haro JM, Brown J. The cost of relapse in patients with schizophrenia in the European SOHO (Schizophrenia Outpatient Health Outcomes) study. Prog Neuropsychopharmacol Biol Psychiatry 2009;33: 835-41
10. Lindenmayer JP, Liu-Seifert H, Kulkarni PM, Kinon BJ, Stauffer V, Edwards SE. Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. J Clin Psychiatry 2009;70:990-6
11. Llorca PM. Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Res 2008;161:235-47
12. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Ser 2004;55:886-91
13. Doering S, Mü ller E, Kö p cke W, Pietzcker A, Gaebel W, Linden M, et al. Predictors of relapse and rehospitalization in schizophrenia and schizoaffective disorder. Schizophr Bull 1998;24:87-98
14. Owens DC, Johnstone EC, Miller P, Macmillan JF, Crow TJ. Duration of untreated illness and outcome in schizophrenia: test of predictions in relation to relapse risk. Br J Psychiatry 2010;196:296-301
15. Liu-Seifert H, Osuntokun OO, Feldman PD. Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia. Compr Psychiatry. 2012;53:107-15. doi: 10.1016/j.comppsych.2010.12.003. Epub 2011 Feb 9
16. Olivares JM, Rodriguez-Morales A, Diels J, Povey M, Jacobs A, Zhao Z, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009;24:287-96
17. American Psychiatric Association.: Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. 4th ed. Washington, DC: American Psychiatric Association, 1994
18. Guy W. Clinical Global Impressions ECDEU Assessment Manual for Psychopharmacology, revised (DHEW Publ. No. ADM 76-338). Rockville, MD: National Institute of Mental Health. p. 218-22
19. Pharoah F, Mari J, Rathbone J, Wong W. Family intervention for schizophrenia. Cochrane Database Syst Rev 2010 Dec 8;12:CD000088
20. Montero I, Gó m ez-Beneyto M, Ruiz I, Puche E, Adam A. The infl uence of family expressed emotion on the course of schizophrenia in a sample of Spanish patients. A two-year follow-up study. Br J Psychiatry 1992;161:217-22
21. Vaughan K, Doyle M, McConaghy N, Blaszczynski A, Fox A, Tarrier N. The relationship between relative's Expressed Emotion and schizophrenic relapse: an Australian replication. Soc Psychiatry Psychiatr Epidemiol 1992;27:10-5
22. Ramí rez Garcí a JI, Chang CL, Young JS, Ló p ez SR, Jenkins JH. Family support predicts psychiatric medication usage among Mexican American individuals with schizophrenia. Soc Psychiatry Psychiatr Epidemiol 2006;41:624-31
23. Sellwood W, Tarrier N, Quinn J, Barrowclough C. The family and compliance in schizophrenia: the infl uence of clinical variables, relatives ' knowledge and expressed emotion. Psychol Med 2003;33:91-6
24. Farooq S, Large M, Nielssen O, Waheed W. The relationship between the duration of untreated psychosis and outcome in low-and-middle income countries: a systematic review and meta analysis. Schizophr Res 2009;109:15-23
25. Barnes TR, Leeson VC, Mutsatsa SH, Watt HC, Hutton SB, Joyce EM. Duration of untreated psychosis and social function: 1-year follow-up study of fi rst-episode schizophrenia. Br J Psychiatry 2008;193:203-9
26. Black K, Peters L, Rui Q, Milliken H, Whitehorn D, Kopala LC. Duration of untreated psychosis predicts treatment outcome in an early psychosis program. Schizophr Res 2001;47:215-22
27. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, et al. Predictors of relapse following response from a fi rst episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;56:241-7
28. Doering S, Mü ller E, Kö p cke W, Pietzcker A, Gaebel W, Linden M, et al. Predictors of relapse and rehospitalization in schizophrenia and schizoaffective disorder. Schizophr Bull 1998;24:87-98
29. Munk-J ør gensen P, Mortensen PB, Machó n RA. Hospitalization patterns in schizophrenia. A 13-year follow-up. Schizophr Res 1991;4:1-9
30. Mortensen PB, Eaton WW. Predictors for readmission risk in schizophrenia. Psychol Med 1994;24:223-32
31. Gaddini A, Franco F, Di Lallo D, Biscaglia L. Hospitalization for schizophrenia in acute psychiatric wards of the Lazio region: a 4-year follow-up study. Epidemiol Psychiatr Soc 2005;14:227-34
32. Gupta S, Hendricks S, Kenkel AM, Bhatia SC, Haffke EA. Relapse in schizophrenia: is there a relationship to substance abuse? Schizophr Res 1996;20:153-6
33. Swofford CD, Kasckow JW, Scheller-Gilkey G, Inderbitzin LB. Substance use: a powerful predictor of relapse in schizophrenia. Schizophr Res 1996;20:145-51
34. Swofford CD, Scheller-Gilkey G, Miller AH, Woolwine B, Mance R. Double jeopardy: schizophrenia and substance use. Am J Drug Alcohol Abuse 2000;26:343-53
35. Soyka M, Albus M, Kathmann N, Finelli A, Hofstetter S, Holzbach R, et al. Prevalence of alcohol and drug abuse in schizophrenic inpatients. Eur Arch Psychiatry Clin Neurosci 1993;242:362-72
36. Dervaux A, Laqueille X, Bourdel MC, Leborgne MH, Olié JP, L ô o H, et al. Cannabis and schizophrenia: demographic and clinical correlates. Encephale 2003;29:11-17
37. Fazel S, Gulati G, Linsell L, Geddes JR, Grann M. Schizophrenia and violence: systematic review and metaanalysis. PLoS Med 2009;6:e1000120, doi: 10.1371/journal. pmed.1000120
38. Bouza C, Ló p ez-CuadradoT, Amate JM. Physical disease in schizophrenia: a population-based analysis in Spain. BMC Public Health 2010;10:745, doi: 10.1186/1471-2458-10-745
39. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with newgeneration antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003;160:1209-22
40. Peuskens J, Olivares JM, Pecenak J, Tuma I, Bij de Weg H, Eriksson L, et al. Treatment retention with risperidone longacting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr Med Res Opin 2010;26:501-9
41. Naber D, Lambert M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs 2009;23:649-59.